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Background: The REAL-2 trial demonstrated that capecitabine and oxaliplatin were effective alternatives to ﬂuorouracil
and cisplatin, respectively, when used in triplet chemotherapy regimens for previously untreated oesophago-gastric
cancer. The aim of the current analysis was to evaluate the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) in
the REAL-2 cohort.
Material and methods: A post hoc exploratory analysis was carried out on REAL-2 patients with the available absolute
neutrophil count and absolute lymphocyte count. A high NLR was deﬁned using a cut-off value of >3.0. The NLR was
then correlated with clinical outcomes including overall survival (OS), progression-free survival (PFS) and objective re-
sponse rate. Survival curves were generated using the Kaplan–Meier method and comparison between groups was
carried out using Cox regression.
Results: Data were available in 908 of the 1002 REAL-2 participants. Of these, 516 (56.8%) were deemed to have a
high NLR. In univariate analysis, high NLR was associated with a hazard ratio (HR) for OS of 1.73 (1.50–2.00),
P < 0.001, compared with low NLR, equating to median OS values of 9.1 [95% conﬁdence interval (CI) 8.0–9.6] and
12.7 months (95% CI 10.8–14.4), respectively. The NLR remained highly signiﬁcant for OS (P < 0.001) in a multivariate
model including performance status, age, disease extent, presence of liver metastases and presence of peritoneal
metastases. For PFS, high NLR was associated with an HR of 1.63 (1.41–1.87), P < 0.001, compared with low
NLR in univariate analysis. No signiﬁcant interaction was found between NLR status and treatment arm, 13% of all
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patients with low NLR achieving survival beyond 24 months compared with only 6% of patients with high NLR
(P < 0.001).
Conclusion: Our results conﬁrm that high NLR status had a signiﬁcant negative prognostic effect in the REAL-2 trial
population. Based on the multivariate analysis, this effect was independent of other known prognostic factors.
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introduction
Oesophago-gastric cancer (OGC) affects more than 15 000
individuals in the UK every year, and represents one of the
commonest causes of cancer death with 70%–85% of patients
dying within 5 years of diagnosis [1]. This high mortality rate is
primarily a consequence of late diagnosis and limited thera-
peutic options despite signiﬁcant improvements in multidiscip-
linary care [2]. Furthermore, the incidence of oesophageal
adenocarcinoma is rising over the past 20 years, with only 2000
cases in 1995 compared with 3800 cases in 2012. In addition
to the ongoing search for more effective therapeutics, there is
currently a lack of reliable prognostic markers that can guide
decision making for an individual patient and aid clinical trial
stratiﬁcation.
The UK National Cancer Research Institute, phase III
Randomized ECF for Advanced and Locally Advanced
Esophagogastric Cancer 2 (REAL-2) trial demonstrated that
capecitabine and oxaliplatin are as effective as ﬂuorouracil and
cisplatin, respectively, in patients with previously untreated
OGC [3]. Due to the avoidance of indwelling lines and their
complications with use of capecitabine, these results established
both EOX and ECX as standard-of-care options for patients
with advanced OGC. In many centres, oxaliplatin is favoured
over cisplatin due to the shorter infusion time and avoidance of
the large volumes of hydration required to safely administer
cisplatin.
It has been known for many years that chronic inﬂammation
plays an important role in the development and progression of
cancer [4]. Speciﬁcally in relation to OGC, tumours can not only
develop at the sites of inﬂammation, such as Helicobacter pylori
infection, but they can also trigger a regional immune response
around the tumour. Through release of a range of inﬂammatory
factors, the cancer promotes the formation of an inﬂammatory
micro-environment that subsequently aids tumour progression
and metastasis [5]. Neutrophil-to-lymphocyte ratio (NLR) repre-
sents an inexpensive marker of host inﬂammation. A high NLR
has been recently demonstrated to be prognostic in the advanced
disease setting for a variety of solid tumours, including OGC [6,
7]. Additionally, we have previously demonstrated that the NLR
is able to predict the likelihood of discovering peritoneal and/or
metastatic disease at the time of the staging laparoscopy for early-
stage gastric and oesophageal adenocarcinoma [8].
This post hoc exploratory analysis was undertaken within
the REAL-2 trial population and aimed to further evaluate the
prognostic impact of the NLR within a large, prospectively
collected, phase III trial dataset of patients with advanced
OGC. We were also interested in evaluating whether there was
any interaction between the NLR and treatment beneﬁt from
each of the four different chemotherapy regimens evaluated in
this trial.
methods
patients and trial design
The trial design and eligibility criteria have been reported previously. The
primary objective of the phase III REAL-2 study was to evaluate whether
capecitabine and oxaliplatin are at least as effective as ﬂuorouracil and
cisplatin, respectively, in terms of overall survival (OS) (Current Controlled
Trials number, ISRCTN51678883). Eligible patients were enrolled in the trial
from 59 centres in the UK and two centres in Australia between June 2000 and
May 2005. Following enrolment, patients were randomly assigned to receive
one of four triplet therapies: epirubicin and cisplatin plus either ﬂuorouracil
(ECF) or capecitabine (ECX) or epirubicin and oxaliplatin plus either ﬂuorour-
acil (EOF) or capecitabine (EOX).
The eligible population for the current exploratory analysis included all
REAL-2 participants with available white blood cell (WBC), absolute neutro-
phil count (ANC) and absolute lymphocyte count (ALC) data at the time of
trial randomization (before commencement of therapy).
The NLR was calculated using the standard formula: NLR =ANC/ALC [6].
statistical methods
All REAL-2 participants for whom baseline WBC, ANC and ALC data were
available were included in the analysis. It was planned to group patients into
‘high’ and ‘low’ NLR populations based upon a pre-deﬁned cut-off value of
3.0. This cut-off was determined based on prior publications [9–12]. It was
also planned to evaluate the median NLR in our population and evaluate
whether this median value provided more accurate prognostication than the
3.0 cut-off. Kaplan–Meier methods were used to estimate and plot survival
end points. A Cox proportional hazard model was used to assess association
between baseline NLR and survival end points, with hazard ratios (HRs)
being reported. Interactions between treatment group and NLR level were
included in the Cox proportional hazard model to assess whether the treat-
ment effect differed between the NLR groups. Multivariate Cox regression
models were used to assess if NLR association was independent of other
prognostic factors including age; sex; primary tumour site; eastern coopera-
tive oncology group Performance Status (PS 0, 1 or 2); disease extent (locally
advanced, metastatic); liver metastasis; peritoneal metastasis; and alkaline
phosphate.
results
patients
A total of 1002 patients were enrolled in the previously reported
REAL-2 trial. Ninety-four patients for whom there were no ANC/
ALC data were excluded, leaving an eligible population of 908
patients for this exploratory analysis. The median baseline NLR
within our population was 3.7. Using the pre-deﬁned cut-off of
3.0, 516 patients (56.8%) were deemed to have a high NLR.
association of NLR with baseline variables
Table 1 shows baseline characteristics with comparison between
the low NLR and high NLR populations. This table demonstrates
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that an NLR > 3 is signiﬁcantly associated with other adverse prog-
nostic outcomes including poorer WHO PS (2–3) (P≤ 0.001),
greater disease extent (P = 0.021), increased number of metastatic
sites (P = 0.041) and presence of liver metastases (P = 0.004).
association between NLR and patient outcomes
Using the pre-deﬁned cut-off of 3.0, there was found to be a
strong association between NLR level and OS. The HR for OS in
patients with high baseline NLR was 1.73 [95% conﬁdence inter-
val (CI) 1.50–2.00; P < 0.001], compared with the group with low
baseline NLR. The corresponding median OS values were 9.1
months (95% CI 8.0–9.6) in patients with NLR >3 and 12.7
months (95% CI 10.8–14.4) in patients with NLR ≤3. Figure 1
displays the Kaplan–Meier curves for OS for the two NLR groups.
Applying the median NLR value of 3.7 as a cut-off, the effect
on OS was similar with an HR of 1.67 (95% CI 1.45–1.92;
P < 0.001) in the high NLR group. As this HR is lower than that
reported with the cut-off value of 3.0, this median cut-off does
not appear to improve the prognostic accuracy. Further analyses
were therefore undertaken using the pre-planned 3.0 cut-off only.
In relation to progression-free survival (PFS), the same trend
was revealed as for OS with an HR of 1.63 (95% CI 1.41–1.87,
P < 0.001) in those with a high baseline NLR compared with the
low baseline NLR group. The corresponding median PFS values
were 6.0 months (95% CI 5.4–6.4) and 8.1 months (95% CI 7.0–
9.2), respectively. Figure 1B displays the Kaplan–Meier curves for
PFS for the two NLR groups.
Objective response rates were similar for low and high NLR
groups, being 47.3% and 42.5%, respectively (odds ratio 0.82;
95% CI 0.63–1.08, P = 0.15).
multivariate analysis
A Cox multivariable analysis model including the previously
described factors, found that NLR, WHO PS, age, extent of
disease, presence of liver or peritoneal metastases were all inde-
pendent predictors of survival (Table 2). The number of meta-
static sites did not reach statistical signiﬁcance (P = 0.105). In
this model, NLR was associated with an adjusted HR of 1.67
(95% CI 1.45–1.93) and had a stronger prognostic inﬂuence
than all of the other evaluated variables apart from PS (HR 1.92;
95% CI 1.54–2.39).
association between NLR and beneﬁt from
chemotherapy
Table 3 displays the effect of the NLR on OS in each of the four
different treatment groups included in the REAL-2 trial (ECF,
ECX, EOF and EOX). The HR ranges were similar in all four
groups, ranging from 1.56 in the ECX population to 1.97 in
patients receiving EOX. The interaction test revealed a P value
of 0.55, suggesting no evidence of a signiﬁcant interaction
between NLR value and beneﬁts from a speciﬁc regimen. These
results conﬁrm that the NLR value does not have a predictive
role in relation to treatment selection in our population.
long-term survivors
There were 82 long-term survivors, deﬁned as patients surviving
beyond 24 months. Of these, 51 (62%) had low NLR compared
with 31 (38%) with high NLR. This equated to 13% of all
patients, with a low NLR achieving survival beyond 24 months
compared with only 6% of patients with a high NLR. A test of
proportions provided good evidence of an association between
low baseline NLR and long-term survival (P < 0.001) (Table 4).
discussion
The ﬁndings of our exploratory analysis conﬁrm that a high
baseline NLR was associated with poorer OS and PFS outcomes
among REAL-2 trial participants with advanced OGC. In our
study, we did not ﬁnd any signiﬁcant interaction between NLR
value and the beneﬁt associated with any of the individual treat-
ment regimens evaluated. As such, the NLR does not appear to
have any predictive value in this population and, therefore, does
not alter the interpretation of the previously reported REAL-2
outcomes in an unselected OGC population [3]. One of the
main strengths of our study is the fact that the data arise from
Table 1. Baseline characteristics of the study participants with
comparison between the low (≤3) and high (>3) NLR populations
Group NLR≤ 3
(N = 392)
NLR > 3
(N = 516)
P-value
n % n %
Treatment
ECF 101 25.8 132 25.6 0.983
ECX 102 26.0 129 25.0
EOF 95 24.2 129 25.0
EOX 94 24.0 126 24.4
WHO PS
0–1 368 93.9 443 85.9 <0.001
2–3 24 6.1 73 14.1
Age
<60 years 157 40.1 199 38.6 0.650
≥60 years 235 59.9 317 61.4
Gender
Female 86 21.9 87 16.9 0.054
Male 306 78.1 429 83.1
Site of primary
Gastric 165 42.1 193 37.4 0.152
Oesophago-gastric 227 57.9 323 62.6
Disease extent
Locally advanced 102 26.0 101 19.6 0.021
Metastatic 290 74.0 415 80.4
Type of tumour
Adenocarcinoma 357 91.1 443 85.9 0.174
Squamous 30 77 58 11.2
Other 5 1.3 11 2.1
Number of metastases
0 or 1 257 65.6 304 58.9 0.041
≥2 135 34.4 212 41.1
Liver metastasis
No 252 64.3 283 54.8 0.004
Yes 140 35.7 233 45.2
Peritoneal metastases
No 331 84.4 421 81.6 0.260
Yes 61 15.6 95 18.4
Alkaline phosphatase
<100 U/l 205 54.8 256 52.5 0.492
≥100 U/l 169 45.2 232 47.5
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within a prospectively maintained randomized phase III trial
database. This represents one of the largest individual studies to
evaluate the NLR in OGC and is a relatively homogeneous
group of previously untreated patients. Based on the REAL-2
trial eligibility criteria, these patients are felt to be generally rep-
resentative of the larger population of patients undergoing ﬁrst-
line treatment of advanced OGC. However, as with all phase III
clinical trial data, those patients with a very poor prognosis or
signiﬁcant organ dysfunction will be under-represented.
Overall, the ﬁndings of this analysis are in keeping with the
published literature, with a wealth of recent data across a wide
range of solid organ tumours suggesting that inﬂammation-
based prognostic indicators such as the NLR and the platelet
lymphocyte ratio (PLR) are generally associated with poorer sur-
vival in cancer patient populations [6, 13]. In a systematic
review and meta-analysis of NLR data from 100 studies and a
total of 40 559 patients with various solid tumours, the results
demonstrated that a higher NLR was associated with an adverse
OS outcome (HR 1.81; 95% CI 1.67–1.97; P < 0.001) [6].
Furthermore, this effect was observed across all disease sub-
groups, tumour sites and stages of disease. Similar results were
demonstrated with the PLR in a smaller meta-analysis con-
ducted by the same authors [13]. Utilizing data from 12 754
patients within 20 studies, higher PLR was associated with sig-
niﬁcantly worse OS (HR 1.87; 95% CI 1.49–2.34); P < 0.001).
The NLR and the PLR serve as surrogate markers for an
underlying pro-inﬂammatory tumour micro-environment,
though the exact mechanisms by which this process leads to
poorer cancer outcomes remain uncertain. It is known that the
tumour micro-environment can attract, educate and control
invading leucocytes to promote neo-angiogenesis, and increase
cell viability, motility and invasion [14]. Neutrophils may act as
tumour-promoting leucocytes through production of trans-
forming growth factor-β, interleukin 10 and induction of regula-
tory T-cell pathways which inhibit the normal cytotoxic
response. Circulating neutrophils may also directly secrete a
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Figure 1. (A) Kaplan–Meier estimates of overall according to NLR level. (B) Kaplan–Meier estimates of progression-free survival according to NLR level.
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number of pro-oncogenic factors such as vascular endothelial
growth factor, hepatocyte growth factor and interleukins [15–17].
For these reasons, the stroma around solid organ tumours has
been compared with a poorly healing wound with the persistence
of a wide range of chronic inﬂammatory processes [18]. In add-
ition to processes which may increase the neutrophil count, a
high NLR may also result from a relatively depleted lymphocyte
count. In this scenario, the NLR value may be reﬂective of an
impaired host immune response to malignancy, allowing the
cancer growth to continue relatively unchecked. Indeed, the
converse has been widely reported to be the case—that tumours
with a signiﬁcant inﬁltration of lymphocytes are associated
with a better cytotoxic response and improved survival out-
comes [19, 20].
The main limitation of our analysis is the fact that it is being
carried out post hoc, with multiple comparisons that were not
pre-speciﬁed in the study protocol or the original statistical
plan. For this reason, the current ﬁndings are regarded as entire-
ly exploratory. Another limitation is the lack of serial NLR
values for each patient during their ﬁrst-line chemotherapy.
While the baseline NLR is undoubtedly of prognostic value,
there are now additional data suggesting that increases or
decreases in the NLR during treatment may also be of import-
ance. In particular, data from a couple of published series have
suggested that normalization of a high baseline NLR value
during chemotherapy is associated with signiﬁcant improve-
ments in OS or PFS when compared with those with a persist-
ently high NLR value throughout [21, 22]. As a dynamic
marker, serial measurements during treatment could potentially
help to identify those patients who are not deriving beneﬁt from
chemotherapy at an early time point. This requires further evalu-
ation in ongoing trials where samples and data can be collected
and analysed prospectively.
A further important limitation of all of the available data
regarding NLR, including the current study, is the lack of con-
sensus regarding the most appropriate cut-off for evaluation of
the NLR. This is variably reported in the literature and, accord-
ing to the meta-analysis ﬁndings, the median cut-off for the
NLR in the reported studies is 4.0 for OS and 3.0 for PFS [6]. In
our study, we had pre-speciﬁed at the time of formulating the
statistical plan for this analysis that we would use a cut-off of 3.0
for all end points evaluated. However, using the median NLR
value of 3.7 in our population did not add any additional prog-
nostic value and was in fact associated with a lower HR for OS
than the 3.0 cut-off. For the NLR to be useful as a baseline
screening tool for clinicians, there needs to be consensus regard-
ing the deﬁnitions of ‘high’ versus ‘low’ NLR. This would also
greatly aid the use of the NLR as a stratiﬁcation factor in future
clinical trials.
In conclusion, a high NLR was negatively prognostic for both
OS and PFS in patients with advanced OGC receiving ﬁrst-line
chemotherapy within the randomized phase III REAL-2 trial.
A high NLR of >3 was associated with signiﬁcantly shorter
Table 2. Overall survival multivariate model
Hazard ratio 95% Confidence interval P value
NLR
≤3 1.0
>3 1.67 1.45–1.93 <0.001
WHO PS
0–1 1.0
2–3 1.92 1.54–2.39 <0.001
Age
<60 years 1.0
≥60 years 0.85 0.74–0.98 0.029
Disease extent
Locally advanced 1.0
Mets 1.24 1.01–1.52 0.036
Liver metastasis
No 1.0
Yes 1.33 1.13–1.57 0.001
Peritoneal metastases
No 1.0
Yes 1.57 1.29–1.91 <0.001
Table 3. Efficacy of treatment stratified by NLR for each of the four chemotherapy regimens evaluated in the REAL-2 trial
NLR group Treatment Number of subjects Number of events Median OS (95% CI) Hazard ratio (95% CI) P value
ECF ≤3 101 80 12.0 9.8–14.2 1.0
>3 132 124 7.9 6.5–10.7 1.62 1.22–2.16 0.001
ECX ≤3 102 84 11.1 9.1–15.3 1.0
>3 129 121 9.6 8.3–11.0 1.56 1.17–2.07 0.002
EOF ≤3 95 75 14.7 10.3–16.8 1.0
>3 129 122 8.4 6.8–9.5 1.89 1.41–2.53 <0.001
EOX ≤3 94 65 14.3 9.9–18.9 1.0
>3 126 118 9.8 7.4–11.8 1.97 1.45–2.68 <0.001
P-value for interaction = 0.55.
Table 4. Association of NLR with long-term survivorship
(>24-month survival)
Group NLR≤ 3
(N = 392)
NLR > 3
(N = 516)
P-value
n % n %
Long-term survivor
≤24 months 341 87.0 485 94.0 <0.001
>24 months 51 13.0 31 6.0
Volume 27 | No. 4 | April 2016 doi:10.1093/annonc/mdw012 | 
Annals of Oncology original articles
survival across all four of the treatment regimens evaluated and
was not found to have any role as a predictive biomarker in our
dataset. The NLR could provide important additional prognostic
information for patients and clinicians in daily practice and may
be a relevant stratiﬁcation factor in future clinical trials.
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